Wordt geladen...
Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most common adult leukemia, with an overall poor prognosis. New agents targeting various receptors may improve treatment outcomes and overall survival. FMS-like tyrosine kinase 3 (FLT3) is a targetable mutation occurring in one third of AML patients. It contribute...
Bewaard in:
| Gepubliceerd in: | J Adv Pract Oncol |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Harborside Press LLC
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7517771/ https://ncbi.nlm.nih.gov/pubmed/33542854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2020.11.1.7 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|